Prof Bieber opened the symposium by explaining that there has been a revolution in the management of patients with moderate-to-severe atopic dermatitis (AD) since the approval of the first biologic, dupilumab, in 2017.
Trichotillomania with Giant Gastric Trichobezoar in a Female Child: A Case Report
10 Mins
